首页   按字顺浏览 期刊浏览 卷期浏览 Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung Ca...
Cisplatin and Etoposide as Second-Line Chemotherapy in Patients with Small Cell Lung Cancer

 

作者: FigoliFranco,   VeronesiAndrea,   ArdizzoniAndrea,   CanobbioLuciano,   BruschiGioia,   MazzaFrancesco,   ZagonelVittorina,   Lo ReGiovanni,   RossoRiccardo,   MonfardiniSilvio,  

 

期刊: Cancer Investigation  (Taylor Available online 1988)
卷期: Volume 6, issue 1  

页码: 1-5

 

ISSN:0735-7907

 

年代: 1988

 

DOI:10.3109/07357908809077023

 

出版商: Taylor&Francis

 

数据来源: Taylor

 

摘要:

AbstractTwenty-seven evaluable patients with small cell lung cancer (SCLC) resistant to, or relapsed after induction combination chemotherapy (CT) were treated with etoposide (VPJ6) plus cisplatin (DDP). Previous treatment was: alternating CT with cyclophosphamide (C), adriamycin (A), methotrexate (M), procarbazine (P) (CAMP)/VP16, BCNU (B), hexamethylmelamine (H) (VP16BH) in 16 patients; C, A, vincristine (CAV) in 6 patients; C, A, and VP16 (CAVP16) in 5 patients. We observed 2 (7%) complete responses (CR) and 9 (33%) partial responses (PR). Duration of CRs was 8 and 14 weeks, respectively. PRs lasted a median of 22 weeks (range 16-44). Seven of 21 (33%) patients previously treated with VP16 responded to DDP plus VP16 (D-V). These results confirm D-V regimen as active in SCLC patients even when heavily pretreated. Our 33 % response in patients who had VP16 in their induction treatment regimen provides further evidence of an important potentiating effect of DDP, as reported in animal system.

 

点击下载:  PDF (347KB)



返 回